Het molecuul dat je darmen met je hart verbindt: 5 verrassende feiten over TMAO
De onzichtbare metabole estafette: Een meta-organisme-as
Human health was once viewed through a purely genomic lens, yet emerging research into the gut-organ axis reveals that our physiology is managed by a “meta-organismal” relay. In this biochemical hand-off, dietary precursors are processed by the enteric microbial ecosystem into volatile intermediates, which are subsequently modified by host organs to produce systemic effects.At the center of this interface is trimethylamine N-oxide (TMAOTMAO is a compound your gut bacteria produce from nutrients found in red meat, eggs, and some fish. Higher blood levels have been linked to heart disease.). Historically known as an obscure marine osmolyte used by deep-sea fish to maintain fluid balance, TMAO has transitioned into a primary target for cardiovascular risk stratification. It is now recognized as a potent predictor of Major Adverse Cardio and Cerebrovascular Events (MACCE), often providing prognostic power that exceeds traditional lipid panels. The question for modern medicine has become: how does a single molecule, synthesized at the intersection of diet and the microbiome, dictate the trajectory of systemic disease?
Je microbioom is een chemische fabriek (en je lever is de kwaliteitscontrole)
De synthese van TMAO is een nauwkeurig proces in meerdere stappen dat een verplichte bijdrage van darmbacteriën vereist. Zonder specifieke microbiële enzymen zouden de precursors die we eten nooit worden omgezet in dit pro-atherogene molecuul.
- De Microbiële Toegangspoort: When we consume cholineCholine is a nutrient found in eggs, red meat, and liver. Your body genuinely needs it, especially for the brain. (eggs, dairy) or L-carnitineL-carnitine is a compound abundant in red meat that plays a role in fatty acid transport into mitochondria; gut bacteria can convert it through several steps—including the intermediate γ-butyrobetaine—into TMA and ultimately TMAO. The article cites it as the other major dietary precursor studied in TMAO research. (rood vleesRed meat includes beef, pork, and lamb.), microbial enzymes—specifically those encoded by the cutC/D en cntA/B genen—kloven deze verbindingen om trimethylamine (TMA) te produceren.
- De $\gamma$ BB Nuance: Crucially, the carnitineCarnitine is a nutrient found mostly in red meat. Your body also makes some on its own. pathway involves a significant metabolic intermediate: $\gamma$ -butyrobetaine ( $\gamma$ BB). In the proximal gut, L-carnitine is converted into $\gamma$ BB at a rate approximately 1,000-fold higher than direct TMA formation, serving as a primary reservoir for subsequent TMA production by specialized microbiota.
- Leveroxidatie: TMA travels via the portal vein to the liver, where it is oxidized into odorless TMAO by the flavin-containing monooxygenase 3 (FMO3) enzyme.”The production of TMAO is not a direct result of human cellular metabolism but rather a ‘meta-organismal’ process that requires an obligatory contribution from the gut microbiota.”FMO3 activity is not static; it is regulated by host factors including the farnesoid X receptor (FXR)The farnesoid X receptor (FXR) is a nuclear bile acid receptor expressed predominantly in the liver and intestine that, among its many functions, regulates the activity of FMO3 — the hepatic enzyme responsible for converting TMA into TMAO — thereby influencing systemic TMAO levels. en bile acidsGalzuren worden door je lever gemaakt uit cholesterol en afgegeven aan de darm om te helpen bij de vertetering van vet.. When this hepatic “quality control” fails due to genetic polymorphisms, TMA accumulates, resulting in trimethylaminuria (fish odor syndrome)Trimethylaminuria is a metabolic disorder caused by reduced FMO3 enzyme activity — often due to genetic polymorphisms — in which TMA cannot be efficiently oxidized to odorless TMAO in the liver, causing TMA to accumulate and be excreted through sweat, breath, and urine, producing a characteristic fishy odor.. Under normal conditions, however, the liver efficiently converts the volatile gas into systemic TMAO, which then circulates as a bioactive metabolite.
The “Fish Paradox”—Why Seafood Isn’t the Enemy
Vis is van nature rijk aan reeds gevormd TMAO. Daarom kan een enkele portie vis de TMAO-waarden in het plasma aanzienlijk hoger doen stijgen dan een portie rood vlees. Toch bevestigen epidemiologische gegevens consequent dat visconsumptie cardioprotectief is. Deze ogenschijnlijke tegenstrijdigheid wordt opgelost door drie verschillende factoren:
- De metabole route: Fish-derived TMAO is absorbed directly into the bloodstream. In contrast, meat-derived precursors must undergo microbial fermentation to produce TMA. This microbial process is often associated with other inflammatory byproducts or shifts in the microbiome (“guilt by association”) that are absent when consuming pre-formed TMAO from fish.
- Voedingswaardecompensatie: Vis en schaaldieren leveren hoge concentraties omega-3-meervoudig onverzadigde vetzuren (EPA en DHA). Deze ontstekingsremmende verbindingen kunnen de potentiële signaleringsschade van een voorbijgaande TMAO-piek effectief tegengaan.
- Tijdelijke vs. chronische blootstelling: In individuals with healthy renal function, fish-induced TMAO is cleared via glomerulaire filtratieGlomerulaire filtratie is het proces waarbij de glomeruli van de nieren — kleine capillaire netwerken — afvalstoffen en kleine moleculen, waaronder TMAO, uit de bloedbaan filteren naar de urine; een adequate glomerulaire filtratie verwijdert uit vis afkomstige TMAO binnen ongeveer 24 uur, terwijl een chronische nierziekte deze klaring vermindert en ervoor zorgt dat TMAO zich ophoopt. within 24 hours. Conversely, meat-heavy diets foster a microbiome optimized for chronic TMA production, leading to sustained, elevated baseline levels that are far more damaging than acute, diet-induced fluctuations.
TMAO is a “Rheostat” for Your Blood’s Clotting Risk
TMAO does not directly trigger coagulation; rather, it functions as a pro-thrombotic sensitizerA pro-thrombotic sensitizer is an agent that does not directly initiate blood clot formation but lowers the activation threshold of platelets, making them hyperreactive to normal clotting stimuli such as thrombin or collagen; TMAO acts as a pro-thrombotic sensitizer by promoting calcium release from the platelet dense tubular system.. It acts as a biochemical reostaat , “dialing up” the reactivity of bloedplaatjesPlatelets are small, anucleate cell fragments in the blood whose primary role is to clump together at sites of vascular injury to form a clot and stop bleeding; because they cannot synthesize new protein, aspirin's irreversible inhibition of their clotting enzyme lasts for the platelet's entire 7–10 day lifespan. to primary agonists like thrombin or collagen.The molecular mechanism involves the modulation of intracellular calcium ( $Ca^{2+}$ ) signaling. TMAO facilitates the rapid release of $Ca^{2+}$ from internal stores—specifically the dicht buisvormig systeem —within the platelets. This heightened calcium flux makes platelets “twitchier” and more prone to aggregation under high-shear conditions, increasing the risk of myocardinfarctZie Hartinfarct voor de volledige vermelding. en beroerteEen beroerte ontstaat wanneer de bloedtoevoer naar een deel van de hersenen stopt, hetzij door een blokkade of door een bloeding.. The causal nature of this link was demonstrated by the removal of the microbial knippenC gene in experimental models; eliminating the gut’s ability to produce the TMA precursor completely abolished this heightened thrombotic potential.
Voorbij het hart: de verbinding tussen hersenen en nieren
While TMAO is a staple of cardiovascular research, it is increasingly viewed as a global marker of health, with profound implications for the “Microbiota-Gut-Brain Axis” and renal longevity.
- Neurodegeneratie TMAO passeert gemakkelijk de bloed-hersenbarrière. In het centrale zenuwstelsel fungeert het als een chemische chaperonne die de aggregatie van amyloïde-bèta en $\alpha$ -synucleïne versnelt. Bovendien zet het pyroptosePyroptosis is a form of inflammatory programmed cell death, distinct from apoptosis, that is triggered by activation of inflammasome complexes such as NLRP3; in the context of TMAO, it refers to the death of oligodendrocytes in the brain driven by ROS-NLRP3 signaling, contributing to demyelination and cognitive decline. of oligodendrocytenOligodendrocytes are glial cells in the central nervous system responsible for producing myelin, the insulating sheath that wraps around nerve fibers and enables rapid electrical signal transmission; TMAO-induced pyroptosis of oligodendrocytes causes demyelination, impairing neural communication and contributing to cognitive decline. via de ROS-NLRP3-signaleringsroute , wat neuro-ontsteking en demyelinisatie bevordert die vaak worden waargenomen bij cognitieve achteruitgang.
- De Vicious Circle van de Nieren: TMAO is primarily cleared by the kidneys, but it also acts as a “uremische toxineA uremic toxin is a waste product that accumulates to harmful concentrations in the blood when kidney function is severely impaired and cannot clear it adequately; the article describes TMAO as behaving like a uremic toxin only at the very high, 'supraphysiological' levels seen in advanced kidney disease. At normal kidney function it is considered a harmless passenger..” Elevated levels promote fibrose van renaal tubulo-interstitieel weefsel and glomerular sclerosis. This creates a destructive feedback loop: declining kidney function leads to higher TMAO retention, which in turn accelerates further renal damage.This multi-organ impact explains why multi-omics data from the UK BiobankUK Biobank holds detailed genetic, lifestyle, and health data on half a million British volunteers, linked to their medical records. shows that TMAO levels add significant predictive power across 17 different disease categories, reflecting systemic biological stress.
“Drugging the Microbiome” Without Killing It
Traditional approaches to microbiome modulation involved broad-spectrum antibiotics, which act as a “scorched earth” strategy. The future of TMAO management lies in “non-lethal” small-molecule inhibitors that target the enzyme (TMA lyase) rather than the bacteria themselves, avoiding the risk of antibiotic resistance.| Inhibitor Class | Key Compound | Mechanism of Action | Potency & Status || —— | —— | —— | —— || Competitieve remmers | DMB (found in olijfolieOlive oil is the main fat of the Mediterranean diet, rich in monounsaturated fat and, in the extra virgin form, in plant compounds called polyphenols.) | Mimics choline to competitively block CutC/D | Preclinical; naturally occurring || Zelfmoordsubstraten | IMC / FMC | Onomkeerbaar bindt het CutC/D-enzym en deactiveert dit Nanomolaire potentie ( $IC_{50}$ ); hoog veiligheidsprofiel |
Verbindingen zoals jodiummethylcholine (IMC) hebben het vermogen aangetoond om systemisch TMAO te verlagen en het trombotisch risico te verminderen zonder de bloedingstijd te verlengen, wat een paradigmaverschuiving in de precisie-microbioomfarmacologie vertegenwoordigt.
Conclusie: Naar gepersonaliseerde preventie
TMAO serves as a high-fidelity mirror reflecting the interface between our dietary inputs and our internal microbial ecosystem. It is no longer just a biomarkerEen biomarker is iets meetbaars in het lichaam dat iets vertelt over gezondheid of ziekte — een labwaarde, een scanresultaat, een bloeddrukmeting.; it is a bioactive participant in the pathogenesis of cardiovascular, renal, and neurodegenerative diseases.As we transition toward “stratified nutrition,” an individual’s gut profile—specifically the abundance of microbial knippenC genes and the activity of hepatic FMO3—will likely dictate personalized dietary interventions. By identifying “high TMA-producers” early, we can move beyond generalized advice toward targeted microbiome management. The state of your heart is, quite literally, a reflection of the invisible metabolic relay occurring in your gut. What is your internal factory producing?
Diepgaand onderzoek naar TMAO
De meta-organisme meta-as van trimethylamine-N-oxide: Een uitgebreide analyse van biochemische routes, cardiometabole pathogenese en klinische implicaties
The emergence of trimethylamine N-oxide (TMAO) as a central player in cardiometabolic medicine represents a major shift in how researchers understand the interaction between diet, the darmmicrobioomThe gut microbiome is the enormous community of bacteria living in your intestines. There are trillions of them, and they are not passive passengers., and human health. TMAO, a small organic compound with the molecular formula C5H11NO2, is a water-soluble amine N-oxide that has moved from being a relatively obscure osmolyte in marine biology to a widely studied candidate biomarker and potential mediator of cardiovascular risk. The synthesis of TMAO is a multi-step process that bridges the external environment (diet), the enteric microbial ecosystem (gut microbiota), and the host’s internal physiology (liver and kidneys). This report provides an exhaustive, expert-level deep dive into the TMAO axis, analyzing its biochemical architecture, the molecular mechanisms through which it may promote disease, the clinical evidence supporting its prognostic value, and the contemporary controversies regarding its status as a causal agent versus a surrogate biomarker of systemic dysbiosis and cardiometabolic risk.
Het biochemisch landschap: de darm-lever-nier-as
De productie van TMAO is niet het directe resultaat van het menselijke cellulaire metabolisme, maar eerder een meta-organismair proces dat een verplichte bijdrage vereist van de darmmicrobiota. Deze route wordt in gang gezet wanneer precursoren uit de voeding worden geconsumeerd en vervolgens worden omgezet in vluchtige intermediairen die de gastheer vervolgens modificeert.
Voedingsprecursoren en de microbiële toegangspoort
De belangrijkste grondstoffen voor de synthese van TMAO zijn quaterner ammoniumverbindingen die in overvloed te vinden zijn in veel dierlijke voedingsmiddelen, hoewel sommige plantaardige voedingsmiddelen hier ook aan bijdragen via hun gehalte aan betaine en choline. De meest prominente precursoren zijn choline (vaak in de vorm van fosfatidylcholine of lecithine), L-carnitine, betaine, γ-butyro-beëtine, en crotonobetaïne.
| Dieetvoorloper | Primaire voedselbronnen | Metabool tussenz produktu | Eindproduct van het systeem |
| Choline / Fosfatidylcholine | Eigeel, lever, zuivel, soja | Trimethylamine (TMA) | Trimethylamine-N-oxide (TMAO) |
| L-Carnitine | Rood vlees (rundvlees, lamsvlees), supplementen | γ-Butyro-bèt\u00eane (γBB)γ-Butyrobetaine (γBB) is een belangrijk metabolisch intermediair dat wordt gevormd in de proximale darm wanneer bacteriën beginnen met het verwerken van L-carnitine uit de voeding; het hoopt zich op met een snelheid die ongeveer 1.000 keer hoger is dan de directe TMA-vorming en dient als een reservoir dat de productie van TMA and TMAO in stand houdt lang nadat een vleeshoudende maaltijd is verteerd. / TMA | Trimethylamine-N-oxide (TMAO) |
| γ-butyro-be-aïne | Vooraf gevormd in sommige rode soorten vlees; microbiële intermediair | Trimethylamine (TMA) | Trimethylamine-N-oxide (TMAO) |
| Betaine | Bieten, spinazie, volkoren granen | Trimethylamine (TMA) | Trimethylamine-N-oxide (TMAO) |
| Crotonobetaïne | bijproduct van carnitinemetabolisme | Trimethylamine (TMA) | Trimethylamine-N-oxide (TMAO) |
The transformation of these nutrients begins in the intestinal lumenHet lumen is het open kanaal in een bloedvat waar het bloed daadwerkelijk stroomt.. Dietary choline and carnitine are metabolized by specific microbial enzymes. The cleavage of the carbon-nitrogen bond in choline is catalyzed by the glycyl radical enzyme choline trimethylamine-lyase, encoded by the knippenC gene, and its activating eiwitEiwit is de voedingsstof die je lichaam gebruikt om spieren en weefsel op te bouwen en te herstellen., gecodeerd door snijdD. Deze reactie stelt trimethylamine (TMA) vrij als een vluchtig bijproduct. Op vergelijkbare wijze kan L-carnitine worden gemetaboliseerd via een afzonderlijke route waarbij het carnitine-monooxygenasesysteem (gecodeerd door aantalA en cntB), wat tevens resulteert in de productie van TMA.
Rec reciente onderzoek heeft aanzienlijke nuance toegevoegd aan de carnitineroute door te identificeren gamma-butyrobetaine (γBB) as a major intermediary metabolite. Following the ingestion of L-carnitine, γBB is produced at a rate approximately 1,000-fold higher than the direct formation of TMA in the proximal gut. This γBB is then converted into TMA by a specialized subset of the microbiota in a secondary step. The presence of these intermediates suggests that the gut’s metabolic capacity for TMAO precursors is not a single-step reaction but a complex relay between different microbial taxa.
Leveromzetting en de rol van FMO3
Zodra TMA in de darm is geproduceerd, wordt het opgenomen door het darmepitheel en via de poortader naar de lever getransporteerd. TMA is een zeer vluchtige, kwalijk ruikende verbinding; bij de mens is de snelle omzetting in het geurloze TMAO een cruciale ontgiftingsstap. Deze oxidatie wordt gekatalyseerd door de familie van flavine-bevattende mono-oxygenase (FMO) enzymen, in het bijzonder de FMO3 isovorm, die verantwoordelijk is voor de overgrote meerderheid van de omzetting van TMA naar TMAO in de lever.
De activiteit van FMO3 is een belangrijke bepalende factor voor de circulerende TMAO-spiegels. Genetische polymorfismen in de FMO3 gene can lead to reduced enzymatic activity, resulting in the accumulation of TMA and the condition known as trimethylaminuria, or fish-odor syndrome, where TMA is excreted in sweat, breath, and urine. Conversely, increased FMO3 activity – which is influenced by host factors including bile-acid signaling and FXR-related pathways – can raise systemic TMAO concentrations even in the absence of extreme precursor intake. After its formation in the liver, TMAO enters the systemic circulation and is primarily eliminated by the kidneys through glomerular filtration.
Moleculaire werkingsmechanismen: Hoe TMAO ziekte kan veroorzaken
The pathogenicity of TMAO has been linked to a diverse range of mechanisms that influence cellular stress, inflammatory signaling, tromboseTrombose is een bloedstolsel dat zich vormt in een bloedvat., and lipid homeostasis. Experimental models have moved beyond simple correlation to identify intracellular targets that TMAO may modulate at physiologic or pathophysiologic concentrations. Still, many of these mechanisms remain best established in preclinical systems rather than definitive human intervention studies.
Cholesterolmetabolisme en omgekeerd cholesteroltransport
One of the hallmark pro-atherogenic mechanisms attributed to TMAO is disruption of cholesterolCholesterol is een wasachtige stof die je lichaam nodig heeft. Het zit in celwanden, hormonen, vitamine D en de gal die je voedsel verteert. Je zou zonder sterven. homeostasis. Under normal conditions, the body maintains balance through omgekeerd cholesteroltransportReverse cholesterol transport is the process of moving cholesterol out of tissues, including artery walls, and back to the liver for disposal. HDL particles do the hauling. (RCT), where excess cholesterol from peripheral macrofagenEen macrofaag is een grote immuuncel die vuur en indringers opslokt. De naam betekent letterlijk "grote eter"." is transported back to the liver for excretion in bile. TMAO has been shown in animal models to impair this process.
In muismodellen leidt suppletie met TMAO via de voeding tot een afname van het RCT-vermogen met ongeveer 35%. Deze verslechtering lijkt via verschillende parallelle mechanismen tot stand te komen:
- Macrofaag SchuimcelEen schuimcel is een immuuncel die zoveel ingesloten cholesterol heeft opgenomen dat deze opzwelt en er onder een microscoop schuimig uitziet. Formation: TMAO reguleert de expressie van scavenger-receptoren op, in het bijzonder CD36 en scavenger-receptor A (SR-A), which facilitate the uptake of modified LDLLDL, of lage-dichtheid-lipoproteïne, is het belangrijkste deeltje dat cholesterol door uw bloed vervoert — en het belangrijkste dat vast komt te zitten in de wanden van slagaders. into macrophages. This increases the rate at which macrophages are converted into pro-inflammatory foam cells within the arterial wall.
- Galzuurremming: TMAO onderdrukt de expressie van belangrijke leverenzymen die betrokken zijn bij de synthese van galzuren, met name CYP7A1CYP7A1 (cholesterol 7-alpha-hydroxylase) is the rate-limiting liver enzyme that initiates the conversion of cholesterol to bile acids, representing the primary route by which the body eliminates cholesterol. Because the sterol ring cannot be broken down for energy, this hepatic conversion to bile acids is the main disposal mechanism. en CYP27A1. Door de omzetting van cholesterol in galzuren te verminderen, kan TMAO een belangrijke route voor uitscheiding van cholesterol beperken.
- Galzuurtransport: Proteomische studies hebben gesuggereerd dat TMAO de abundantie van galzuurtransporters downreguleert, wat de flux van cholesterolmetabolieten verder verstoort en ophoping bevordert.
Endotheeldisfunctie en het NLRP3-inflammasoom
TMAO acts as a stimulus for vascular ontstekingOntsteking is de reactie van je immuunsysteem op letsel of iets dat het als een indringer beschouwt. Het brengt zwelling, warmte en opruimingscellen teweeg. en endotheeldisfunctieEndotheeldisfunctie is wanneer die dunne bekleding zijn werk niet meer goed doet. Bloedvatten verwijden zich niet goed en de barrière wordt lekkerder., both of which are important early steps in atherogeneseAtherogenese is het stapsgewijze proces van de vorming van een plaque.. One frequently discussed pathway in this context is activation of the NLRP3-inflammasoomThe NLRP3 inflammasome is an intracellular protein complex in immune cells that, when activated by cholesterol crystals, oxidized lipids, or other danger signals within an atherosclerotic plaque, triggers the release of the inflammatory cytokines interleukin-1β and interleukin-6, accelerating plaque growth and instability..
The proposed mechanism involves mitochondrial dysfunction and the accumulation of mitochondrial reactieve zuurstofcomponentenReactive oxygen species are unstable oxygen-containing molecules produced as a by-product of normal metabolism. (mtROS). TMAO has been reported to suppress expression of the mitochondrial deacetylase SIRT3, wat leidt tot hyperacetylering en een verminderde activiteit van superoxide-dismutase 2 (SOD2). This loss of antioxidantEen antioxidant is een stof die schadelijke moleculen in het lichaam opruimt. Vitamine E en bètacaroteen zijn hiervan voorbeelden. buffering may promote an oxidative burst that activates thioredoxine-interagerend eiwit (TXNIP), which in turn triggers assembly of the NLRP3NLRP3 is an alarm system inside immune cells. When it detects something it treats as a threat, it triggers a burst of inflammatory signaling. inflammasome. Inflammasome activation then promotes cleavage of pro-caspase-1 and release of the pro-inflammatory cytokines IL-1β en IL-18.
| Signaleringsroute | Cellulair effect van TMAO | Pathologisch resultaat |
| NLRP3 / TXNIP | Activering van inflammasoom en cytokinenrelease (IL-1β, IL-18) | Endotheelontsteking, vaatletsel |
| NF-κB | Increased expression of VCAM-1VCAM-1 is een kleverig molecuul dat verschijnt op een ontstoken vaatwand en voorbijkomende witte bloedcellen grijpt zodat ze in de wand kunnen binnendringen. en ICAM-1ICAM-1 is een molecuul dat verschijnt op het oppervlak van de bekleding van de bloedvaten en werkt als klittenband, dat passerende immuunellen vangt. | Versterkt leukocytenadhesieThe process by which white blood cells attach to the endothelial surface of blood vessels, a key early step in atherogenesis; nitric oxide and an intact glycocalyx normally suppress this adhesion. and migration |
| MAPK / ERK | Fosforylering van IκB-gerelateerde inflammatoire signaaltransductieknooppunten | pro-inflammatoire gentranscriptie |
| PERK (UPR) | Activering van endoplasmatisch-reticulumstresssignalisering | FoxO1-inductie en metabole disfunctie |
Beyond inflammation, TMAO may also interfere with endothelial self-repair. In cell-based studies, it impairs the proliferation and migration of human umbilical vein endotheelcellenThe thin layer of cells lining the inner surface of all blood vessels; they regulate vascular tone, prevent clotting, and control the passage of substances into the artery wall — and their dysfunction is an early, critical step in atherosclerosis. (HUVECs) and can activate protein kinase C (PKC), further stabilizing a pro-inflammatory endothelial phenotype.
Trombocytethyperreactiviteit en trombotisch potentieel
TMAO wordt vaak omschreven als een pro-trombotische co-metaboliet. Het functioneert niet als een primaire agonist zoals trombine of collageen, maar lijkt in plaats daarvan bloedplaatjes gevoeliger te maken voor deze stimuli. De moleculaire basis voor dit effect ligt in de modulatie van intracellulair calcium (Ca2+) signalering. TMAO faciliteert de afgifte van Ca2+ uit interne bloedplaatjesvoorraden, wat leidt tot verhoogde aggregatie en snellere thrombusvorming onder omstandigheden met hoge afschuifspanning. Belangrijk is dat het wegnemen van het microbiële TMA-genererende vermogen in experimentele systemen dit verhoogde trombotische fenotype elimineert, wat het concept ondersteunt dat het darmmicrobioom kan functioneren als een reostaat voor het systemische stollingsrisico.
Klinisch Bewijs: TMAO als een Globale Prognostische Marker
Since the initial report linking TMAO to hart- en vaatziektenCardiovasculaire aandoeningen is de verzamelnaam voor problemen met het hart en de bloedvaten, waaronder hartinfarcten, beroertes en verstopte beenslagaders. in 2011, multiple prospectieve cohortstudieEen prospectief cohortonderzoek includeert gezonde mensen, registreert hun kenmerken en wacht vervolgens af wat er gebeurt. studies and meta-analyses have evaluated TMAO as an onafhankelijke voorspellerA variable that statistically forecasts an outcome—such as mortality—even after accounting for other known risk factors like age, BMI, and cholesterol through multivariable analysis. of major adverse cardiovascular and cerebrovascular events (MACCE or MACE).
Cardiovasculaire aandoeningen en sterfte door alle oorzaken
Large-scale meta-analyses involving tens of thousands of participants have provided quantitative evidence for a link between higher plasma TMAO and adverse outcomes. One commonly cited meta-analyseEen meta-analyse combineert de resultaten van vele afzonderlijke onderzoeken statistisch tot één algemene schatting. of 14 studies (15,662 participants) found that high plasma TMAO levels were associated with a hazardratioEen hazardratio vergelijkt hoe snel gebeurtenissen plaatsvinden in twee groepen. Een ratio van 0,75 betekent dat gebeurtenissen zich in de behandelde groep voordeden aan driekwart van de snelheid. (HR) of 1.91 voor sterfte door alle oorzakenSterfte door alle oorzaken betekent overlijden door welke oorzaak dan ook, en niet alleen door hartaandoeningen — de meest omvattende en minst te manipuleren uitkomst die een studie kan meten. compared with lower levels.
| Klinisch resultaat | Subjects / Cohorts | Statistical Estimate (HR/RR) | BetrouwbaarheidsintervalEen betrouwbaarheidsinterval is het bereik van waarden dat statistisch compatibel is met wat een studie heeft gevonden. (95%) |
| Sterfte door alle oorzaken | 15,662 subjects | HR: 1.91 | 1.40-2.61 |
| MACCE / MACE | 13,944 subjects | HR: 1.67 | 1.33-2.11 |
| Cardiovascular Events | 10,245 subjects | HR: 1.23 | 1.07-1.42 |
| Mortality (Long-term) | 218 subjects (malnourished) | HR: 2.01 | 1.23-3.31 |
Dose-responseEen dosis-responarelatie betekent dat een grotere hoeveelheid van iets een groter effect oplevert, in een consistent verloop. analyses have suggested that risk rises incrementally with higher TMAO concentrations. In one meta-analysis, every 10 µmol/L increase in plasma TMAO was associated with an approximately 7.6% hoger relatief risicoRelatief risico vergelijkt twee groepen: deze groep had 30 procent minder hartaanvallen dan die groep. of all-cause mortality. These associations often remain statistically significant after adjustment for age, sex, BMI, bloeddrukBloeddruk is de kracht van het bloed dat tegen de wanden van je slagaders duwt. Het wordt genoteerd als twee getallen, zoals 120/80. Het bovenste getal is de druk wanneer je hart samensmelt, het onderste wanneer het ontspant., LDL-cholesterolLDL-cholesterol, of LDL-C, is de hoeveelheid cholesterol in je LDL-deeltjes. Het is het getal op bijna elk standaard laboratoriumrapport., en rokenRoken beschadigt de wand van je bloedvaten, verhoogt de bloeddruk, zorgt ervoor dat het bloed sneller stolt en versneld de groei van plak. status, suggesting that TMAO may capture prognostic information not fully reflected in traditional risicofactorenEen risicofactor is iets dat de kans vergroot dat u een ziekte ontwikkelt — deeltjes met een hoog cholesterolgehalte, hoge bloeddruk, roken, diabetes, familiale belasting. alleen.
Heart Failure and Cardiac Remodeling
Bij patiënten met hartfalenHartfalen betekent dat het hart niet goed genoeg kan pompen om aan de behoeften van het lichaam te voldoen. De naam is misleidend — het betekent niet dat het hart is gestopt. (HF), TMAO levels appear to function as both a marker of disease severity and a possible contributor to progression. HF patients often exhibit higher TMAO levels than healthy controls, with levels correlating with BNP and NYHA functional class. Mechanistically, TMAO has been linked to adverse remodeling through several pathways:
- Fibrosis: TMAO may augment histone methylation and promote endothelial-to-myofibroblast transformation, increasing collagen deposition in the heart.
- Energy Metabolism: TMAO has been linked to impaired myocardial energy handling, including effects on oxidatieve fosforyleringThe mitochondrial process by which cells use oxygen to generate ATP, the body's primary energy currency; aerobic training increases the efficiency of this process, allowing more power output from the same oxygen delivery. and the ATP/creatine phosphate ratio.
- Directe toxiciteit: In some animal models, high-dose TMAO supplementation attenuates the cardioprotective benefits of exercise and worsens myocardial inflammation.
The association of heart failure risk has also been examined in diverse community-based cohorts such as the Cardiovascular Health Study (CHS) en de Multi-Ethnic Study of Atherosclerosis (MESA)A large prospective cohort study of adults initially free of cardiovascular disease that has provided foundational data on coronary artery calcium scoring, demonstrating a strong graded association between CAC burden and future coronary events and validating the risk implications of a CAC score of zero.. In these cohorts, higher concentrations of TMAO (HR 1.15) and its precursor choline (HR 1.44) were independently associated with incident HF, with some analyses suggesting stronger associations in Black and Hispanic/Latino populations.
Chronic Kidney Disease and the Renal Conundrum
The relationship between TMAO and chronische nierziekteChronische nierziekte is een blijvende vermindering van het vermogen van de nieren om afvalstoffen uit het bloed te filteren. (CKD) is complex and bidirectional. Because TMAO is cleared by the kidneys, its concentration rises as renal function declines. In patients with end-stage renal disease (ESRD), TMAO levels can exceed 90 µmol/L, compared with roughly 3 µmol/L in healthy controls.
However, TMAO is not merely a passive marker of kidney damage. Experimental work suggests it may act as a uremic toxin that promotes renal tubulointerstitial fibrosis and glomerular sclerosis. This creates a vicious cycle in which kidney damage leads to higher TMAO, and higher TMAO may further worsen kidney injury. Successful renal transplantation produces a marked fall in plasma TMAO, reinforcing that renal clearance is a primary determinant of systemic levels in this population.
Controversies and Critical Evaluation: Causality vs. Association
The rapid rise of TMAO as a cardiovascular risk factor has been met with substantial scientific scrutiny, particularly around whether it is a causal driver of disease or a marker of a pro-atherogenic diet, impaired renal clearance, or broader microbiome imbalance.
The Fish Paradox
The best-known controversy is the fish paradox. Fish and seafood are naturally rich in pre-formed TMAO, which they use as an osmoprotectant. Consuming fish can lead to immediate and substantial increases in plasma TMAO – often larger than those observed after red-meat feeding. Yet fish intake is consistently associated with cardioprotective dietary patterns and, in many epidemiologic datasets, lower cardiovascular risk.
Several explanations have been proposed:
- Metabolic Route: Fish-derived TMAO is absorbed directly as TMAO, whereas red-meat-derived precursors often require gut microbial conversion to TMA first. The microbial production process may travel with broader dietary and microbiome features that matter independently of TMAO itself.
- Voedingswaardecompensatie: Fish provides omega-3 polyunsaturated fatty acids (EPA and DHA), which may offset or outweigh any potential harm from transient TMAO elevation.
- Transient Exposure: In people with normal renal function, fish-induced TMAO elevations typically return toward baseline within about 24 hours. Chronic microbial production on meat-rich diets may produce more sustained exposure than acute postprandiaalPostprandial means 'after a meal'; postprandial studies measure how the body—including blood vessels, lipid levels, and inflammatory markers—responds in the hours immediately following food consumption, rather than at a fasting baseline. spikes.
Mendelian Randomization and Genetic Insights
To address causality, investigators have used Mendeliana randomisatieMendel-randomisering is een slimme onderzoeksmethode waarbij de genen waarmee mensen zijn geboren, worden gebruikt als een natuurlijk experiment. (MR), which relies on genetic variants as instrumental variables to estimate the effect of an exposure such as TMAO on outcomes such as kransslagaderziekteCoronaire hartziekte is de opbouw van plaque in de slagaders die de hartspier van bloed voorzien. or stroke.
The MR literature is mixed. Some studies have not supported a direct causal relationship between genetically predicted higher TMAO and coronary slagaderEen slagader is een bloedvat dat bloed van het hart wegvoert naar de rest van het lichaam. disease or stroke. This has strengthened the argument that elevated TMAO may sometimes reflect reverse causality, especially when CKD, diabetesDiabetes is een aandoening waarbij de bloedsuikerspiegel te hoog blijft, doordat het lichaam te weinig insuline aanmaakt of niet meer reageert op de insuline die het aanmaakt., or other chronic disorders elevate TMAO secondarily. However, other MR analyses have suggested possible causal relationships with systolische bloeddrukSystolische bloeddruk is het bovenste getal — de druk in je slagaders terwijl je hart samendrukt. and type 2 diabetes risk. These conflicting results imply that, if TMAO is causal, its effects may be pathway-specific, population-specific, or modified by renal function, diet, and host geneticaGenetica is de studie van wat je van je ouders erft..
Confounding by Renal Function and Diet
A major limitation in TMAO research is verwarrendVerstorende vertekening treedt op wanneer een verborgen derde factor twee ongerelateerde dingen met elkaar verbonden doet lijken. by renal function. Because TMAO depends heavily on glomerular filtration, estimated glomerular filtration rate (eGFR) can materially influence any observed association between TMAO and cardiovascular outcomes. Some studies have found that after adjustment for renal markers, the predictive strength of TMAO is attenuated. Diet quality is another major verstorende variabeleA confounder is a variable that is associated with both the exposure being studied (such as TMAO) and the outcome (such as heart disease), making it appear as though one causes the other when a third factor is actually responsible. The article lists renal function, insulin resistance, systemic inflammation, and age as major confounders that inflate the apparent cardiovascular risk of high TMAO in…; higher TMAO often travels with Western-style dietary patterns that are independently linked to cardiovascular risk.
Dietary and Lifestyle Influences on the TMAO Pathway
Since TMAO production is fundamentally a diet-microbiome interaction, lifestyle changes remain a practical first-line strategy for managing elevated levels.
Nutritional Modulation
Dietary patterns strongly shape the metabolic capacity of the gut microbiota.
- Plant-Based and Mediterranean DietsThe Mediterranean diet emphasizes vegetables, fruit, beans, whole grains, nuts, and olive oil, with fish and little red meat.: These patterns are generally associated with lower TMAO levels and with broader cardiometabolic benefit. Higher vezelVezels zijn het deel van plantenvoeding dat je lichaam niet kan vertegenwoordigd. Ze komen voor in bonen, haver, groenten, fruit en volkorenproducten. intake supports a more diverse microbiome and may reduce the abundance or activity of TMA-producing taxa.
- Red Meat and Eggs: These are major contributors of carnitine and choline. Replacing red meat with plant proteins or, in some contexts, white meat can lower TMAO levels substantially over short timeframes.
- De Ketogenic DietA ketogenic diet is very low in carbohydrates and very high in fat, which pushes the body to burn fat and make ketones for fuel.: Because ketogenic diets may rely heavily on eggs, meat, and dairy, they can raise TMAO in some individuals, a consideration that should be weighed against other metabolic effects.
Microbiome-Targeted Strategies
Beyond diet, direct modulation of the gut microbiota is an active area of investigation.
- Antibiotics: Broad-spectrum antibiotics can markedly reduce TMAO production in humans and animal models, but this is not a practical long-term strategy because of resistance, collateral microbiome injury, and rebound effects.
- Probiotics and Prebiotics: Some probiotic strains, particularly Bifidobacterium en Lactobacillus, and prebiotic fibers such as inulin have shown potential to blunt postprandial TMAO responses, though human evidence remains limited and heterogeneous.
Therapeutic Strategies: Pharmacological Inhibition
The most active pharmacologic strategy for lowering TMAO has focused on inhibiting the microbial enzymes that produce TMA, ideally with gut-restricted, non-lethal compounds.
TMA Lyase Inhibitors
The most promising therapeutic avenue is inhibition of microbial TMA lyases, especially the CutC/D system. Unlike antibiotics, these agents are designed to block enzyme activity without killing the bacteria, reducing selective pressure for resistance.
- 3,3-Dimethyl-1-butanol (DMB): A structural analogue of choline present in small amounts in some foods. DMB acts as a competitive inhibitor of microbial TMA lyases. In animal models, DMB reduces plasma TMAO, inhibits foam-cell formation, and attenuates aderverkalkingAtherosclerose is de ziekte achter de meeste hartaanvallen en vele beroertes. Cholesteroldeeltjes raken vast in de vaatwand van een slagader, het lichaam stuurt immuuncellen om op te ruimen, en in de loop van jaren verhardt die bende tot plaque..
- Halomethylcholines (IMC and FMC): Iodomethylcholine (IMC) and fluoromethylcholine (FMC) are second-generation, mechanism-based inhibitors that are substantially more potent than DMB in preclinical work. Studies suggest that IMC can lower TMAO for sustained periods, reshape host cholesterol metabolism, and reduce thrombotic potential without clearly increasing bleeding time in animal models.
| Inhibitor Class | Key Compound | Werkingsmechanisme | Clinical / Research Status |
| Competitive Inhibitor | DMB | Choline analogue; blocks CutC/D | Preclinical |
| Suicide Substrate | IMC / FMC | Irreversibly inhibits CutC/D | Preclinical |
| Hepatic Inhibitor | FMO3 inhibitors | Blocks host TMA oxidation | Limited by toxicity / trimethylaminuria risk |
| Indirect Modulator | Canagliflozin | May alter gut-host metabolic signaling | Clinically approved, but not as a TMAO-specific therapy |
Host Enzyme Inhibition
Inhibiting hepatic FMO3 is another theoretical way to lower TMAO, but the approach is difficult. FMO3 participates in the metabolism of many xenobiotics, and strong inhibition risks off-target toxicity as well as trimethylaminuria, which would likely be poorly tolerated in routine clinical practice.
Emerging Frontiers: Neurodegeneration and Multi-omics
The scope of TMAO research is expanding beyond cardiometabolic disease into neurodegeneration and systems-biology approaches to precision medicine.
TMAO and the Microbiota-Gut-Brain Axis
Emerging studies suggest that TMAO may participate in the pathogenesis of neurodegenerative disease, including Alzheimer’s disease and Parkinson’s disease. TMAO has been detected in cerebrospinal fluid, and experimental work suggests it can influence blood-brain barrier biology and neuroinflammatory signaling.
In the brain, proposed mechanisms include:
- Protein Aggregation: TMAO can function as a chemical chaperone. In disease-relevant contexts, it has been reported to influence aggregation of α-synuclein en amyloid-β.
- Neuroinflammation: TMAO may activate astrocytenAstrocyten zijn een type ondersteunende cellen (glia) in de hersenen die fungeren als de belangrijkste cholesterolproducerende cellen van het centrale zenuwstelsel en cholesterol leveren aan neuronen voor membraanonderhoud en myeline-ondersteuning. Omdat lipoproteïnen in het bloed de bloed-hersenbarrière niet kunnen passeren, zijn de hersenen bijna volledig afhankelijk van de door astrocyten geproduceerde cholesterolsynthese. and microglia, increasing release of inflammatory mediators such as TNF-α en IL-6Interleukine-6, of IL-6, is een signaalmolecuul dat het immuunsysteem gebruikt om een ontstekingsboodschap door het lichaam te verspreiden..
- Demyelination: In hypertensive animal models, TMAO has been linked to oligodendrocyte pyroptosis through ROS-NLRP3 signaling, promoting white-matter injury.
Multi-omics and Precision Medicine
The integration of metabolomics, proteomics, metagenomics, and clinical phenotyping is producing a more complete view of the TMAO axis. Large biobank analyses using machine learning suggest that adding multi-omics features may improve disease prediction beyond traditional clinical markers alone. Precision nutrition is a particularly important future application. By characterizing an individual’s gut microbial TMA-producing capacity – for example, knippenC abundance – along with host genetic features such as FMO3 variants, clinicians may eventually tailor dietary recommendations more precisely.
Critical Evaluation and Future Directions
Despite more than a decade of intensive study, several gaps must be closed before TMAO measurement or targeted reduction becomes standard clinical practice.
Research Gaps and Needs
- Mens Clinical TrialsEen klinische studie is een onderzoek waarbij onderzoekers de ene groep een behandeling en een andere groep een placebo of standaardzorg geven, en vervolgens vergelijken wat er gebeurt.: TMA-lyase inhibition has shown strong promise in animals, but randomized, placebo-controlled human trials are still lacking.
- Causality in Diverse Populations: Mixed Mendelian-randomization findings suggest that TMAO’s role may vary by ancestry, renal function, metabolic status, and baseline diet.
- Standardization of Assays: Broader clinical use would require standardized assays and agreed-upon reference or risk ranges.
- Long-term Effects of Microbiome Modulation: Chronic manipulation of microbial metabolism could have unintended downstream effects that remain poorly characterized.
Conclusion: Should TMAO Be a Clinical Target?
The current evidence supports TMAO as a highly informative marker of the diet-microbiome-host interface and a plausible mechanistic contributor to cardiometabolic disease in at least some settings. Its consistent association with mortality and cardiovascular events, together with biologically plausible mechanisms in preclinical studies, makes it an attractive candidate for risk stratification and future therapeutic targeting.
At the same time, the debate over absolute causality remains unsettled. Renal function, dietary pattern, host genetics, and microbiome composition all complicate interpretation. For now, the most defensible clinical position is that TMAO is a useful research and prognostic biomarker with emerging mechanistic relevance, but not yet a universally accepted stand-alone treatment target. In higher-risk patients, elevated TMAO may still identify an opportunity for stronger dietary counseling, tighter renal and cardiometabolic surveillance, and, eventually, precision microbiome-directed interventions.
Key Takeaways for Clinical Practice
- Synthesis: TMAO is a meta-organismal metabolite produced from dietary choline and carnitine through coordinated actions of the gut microbiota and hepatic FMO3.
- Prognostic Value: Higher plasma TMAO is associated with increased risk of MACE and all-cause mortality; in one meta-analysis, each 10 µmol/L increase was associated with roughly 7.6% higher mortality risk.
- Mechanisms: Proposed disease mechanisms include impaired reverse cholesterol transport, inflammasome activation, endothelial dysfunction, and platelet sensitization.
- Confounding: Interpretation of TMAO should always account for renal function and diet, because kidney clearance is a dominant determinant of circulating levels.
- Intervention: Current management centers on dietary pattern – especially Mediterranean-style or more plant-forward eating – while microbial enzyme inhibitors remain experimental.
- Broad Impact: TMAO is also being studied in neuroinflammation, cognitive decline, and neurodegenerative disease, though those links remain less mature than the cardiovascular literature.
Peer-Reviewed Citation Remap
- Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest. 2014;124(10):4204-4211. doi:10.1172/JCI72331
- Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57-63. doi:10.1038/nature09922
- Chen ML, Zhu XH, Ran L, Lang HD, Yi L, Mi MT. Trimethylamine-N-Oxide Induces Vascular Inflammation by Activating the NLRP3 Inflammasome Through the SIRT3-SOD2-mtROS Signaling Pathway. J Am Heart Assoc. 2017;6(9):e006347. Published 2017 Sep 4. doi:10.1161/JAHA.117.006347
- Tang WHW, Lemaitre RN, Jensen PN, et al. Trimethylamine N-Oxide and Related Gut Microbe-Derived Metabolites and Incident Heart Failure Development in Community-Based Populations. Circ Heart Fail. 2024;17(8):e011569. doi:10.1161/CIRCHEARTFAILURE.124.011569
- Roberts AB, Gu X, Buffa JA, et al. Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. Nat Med. 2018;24(9):1407-1417. doi:10.1038/s41591-018-0128-1
- Koeth RA, Levison BS, Culley MK, et al. γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab. 2014;20(5):799-812. doi:10.1016/j.cmet.2014.10.006
- Cho CE, Caudill MA. Trimethylamine-N-Oxide: Friend, Foe, or Simply Caught in the Cross-Fire?. Trends Endocrinol Metab. 2017;28(2):121-130. doi:10.1016/j.tem.2016.10.005
- Wang Z, Tang WHW, O’Connell T, et al. Circulating trimethylamine N-oxide levels following fish or seafood consumption. Eur J Nutr. 2022;61(5):2357-2364. doi:10.1007/s00394-022-02803-4
- Schiattarella GG, Sannino A, Toscano E, et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. Eur Heart J. 2017;38(39):2948-2956. doi:10.1093/eurheartj/ehx342
- Li X, Geng J, Zhao J, et al. Trimethylamine N-Oxide Exacerbates Cardiac Fibrosis via Activating the NLRP3 Inflammasome. Front Physiol. 2019;10:866. Published 2019 Jul 9. doi:10.3389/fphys.2019.00866
- Hu X, Ren H, Cao Y. The association between trimethylamine N-oxide levels and ischemic stroke occurrence: a meta-analysis and Mendelian randomization study. BMC Neurol. 2023;23(1):413. Published 2023 Nov 21. doi:10.1186/s12883-023-03458-2
- Koeth RA, Levison BS, Culley MK, et al. γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab. 2014;20(5):799-812. doi:10.1016/j.cmet.2014.10.006
- Pathak P, Helsley RN, Brown AL, et al. Small molecule inhibition of gut microbial choline trimethylamine lyase activity alters host cholesterol and bile acid metabolism. Am J Physiol Heart Circ Physiol. 2020;318(6):H1474-H1486. doi:10.1152/ajpheart.00584.2019
- Li XS, Obeid S, Klingenberg R, et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur Heart J. 2017;38(11):814-824. doi:10.1093/eurheartj/ehw582
- Stubbs JR, House JA, Ocque AJ, et al. Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. J Am Soc Nephrol. 2016;27(1):305-313. doi:10.1681/ASN.2014111063
- Tang WH, Hazen SL. Microbiome, trimethylamine N-oxide, and cardiometabolic disease. Transl Res. 2017;179:108-115. doi:10.1016/j.trsl.2016.07.007
- Heianza Y, Ma W, DiDonato JA, et al. Long-Term Changes in Gut Microbial Metabolite Trimethylamine N-Oxide and Coronary Heart Disease Risk. J Am Coll Cardiol. 2020;75(7):763-772. doi:10.1016/j.jacc.2019.11.060
- Wang Z, Roberts AB, Buffa JA, et al. Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis. Cell. 2015;163(7):1585-1595. doi:10.1016/j.cell.2015.11.055
- Vogt NM, Romano KA, Darst BF, et al. The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease. Alzheimers Res Ther. 2018;10(1):124. Published 2018 Dec 22. doi:10.1186/s13195-018-0451-2
- Ji X, Tian L, Niu S, Yao S, Qu C. Trimethylamine N-oxide promotes demyelination in spontaneous hypertension rats through enhancing pyroptosis of oligodendrocytes. Front Aging Neurosci. 2022;14:963876. Published 2022 Aug 22. doi:10.3389/fnagi.2022.963876
- Obeid R, Mohr L, White BA, et al. Circulating trimethylamine N-oxide and cardiovascular, cerebral, and renal diseases including mortality: Umbrella review of published systematic reviews and meta-analyses. Nutr Metab Cardiovasc Dis. 2025;35(8):103908. doi:10.1016/j.numecd.2025.103908
- Zeevi D, Korem T, Zmora N, et al. Personalized Nutrition by Prediction of Glycemic Responses. Cell. 2015;163(5):1079-1094. doi:10.1016/j.cell.2015.11.001